ANI Pharmaceuticals, Inc. (ANIP)
72.18
-0.78
(-1.07%)
USD |
NASDAQ |
Oct 02, 16:00
72.23
+0.05
(+0.07%)
Pre-Market: 20:00
ANI Pharmaceuticals Enterprise Value : 1.893B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.893B |
| October 01, 2026 | 1.911B |
| September 30, 2026 | 1.904B |
| September 29, 2026 | 1.903B |
| September 28, 2026 | 1.954B |
| September 25, 2026 | 1.935B |
| September 24, 2026 | 1.935B |
| September 23, 2026 | 1.944B |
| September 22, 2026 | 2.024B |
| September 21, 2026 | 2.046B |
| September 18, 2026 | 1.984B |
| September 17, 2026 | 1.967B |
| September 16, 2026 | 1.925B |
| September 15, 2026 | 1.891B |
| September 14, 2026 | 1.852B |
| September 11, 2026 | 1.847B |
| September 10, 2026 | 1.876B |
| September 09, 2026 | 1.859B |
| September 08, 2026 | 1.848B |
| September 04, 2026 | 1.871B |
| September 03, 2026 | 1.888B |
| September 02, 2026 | 1.913B |
| September 01, 2026 | 1.887B |
| August 31, 2026 | 1.917B |
| August 28, 2026 | 1.908B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.923B |
| August 26, 2026 | 1.947B |
| August 25, 2026 | 1.972B |
| August 24, 2026 | 1.938B |
| August 21, 2026 | 1.966B |
| August 20, 2026 | 2.011B |
| August 19, 2026 | 2.027B |
| August 18, 2026 | 2.001B |
| August 17, 2026 | 1.981B |
| August 14, 2026 | 1.993B |
| August 13, 2026 | 1.952B |
| August 12, 2026 | 1.960B |
| August 11, 2026 | 1.947B |
| August 10, 2026 | 1.975B |
| August 07, 2026 | 2.032B |
| August 06, 2026 | 2.133B |
| August 05, 2026 | 2.070B |
| August 04, 2026 | 2.054B |
| August 03, 2026 | 2.074B |
| July 31, 2026 | 2.055B |
| July 30, 2026 | 2.082B |
| July 29, 2026 | 2.113B |
| July 28, 2026 | 2.096B |
| July 27, 2026 | 2.035B |
| July 24, 2026 | 2.018B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ocular Therapeutix, Inc. | 1.009B |
| Liquidia Corp. | 2.451B |
| Elanco Animal Health, Inc. | 14.45B |
| Harmony Biosciences Holdings, Inc. | 1.857B |
| Corcept Therapeutics, Inc. | 12.24B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 23.00M |
| Revenue (Quarterly) | 266.04M |
| Total Expenses (Quarterly) | 243.04M |
| EPS Diluted (Quarterly) | 1.052 |
| Gross Profit Margin (Quarterly) | 54.97% |
| Profit Margin (Quarterly) | 8.65% |
| Earnings Yield | 6.42% |
| Operating Earnings Yield | 8.38% |
| Normalized Earnings Yield | 5.049 |